Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease

Author(s):  
Julien Kirchgesner ◽  
Rishi J. Desai ◽  
Laurent Beaugerie ◽  
Sebastian Schneeweiss ◽  
Seoyoung C. Kim
Sign in / Sign up

Export Citation Format

Share Document